Opportunity Information: Apply for HRSA 16 188
Apply for HRSA 16 188
- The HHS-HRSA in the health sector is offering a public funding opportunity titled "Jurisdictional Approach to Curing Hepatitis C Among HIV/HCV Coinfected People of Color - Evaluation and Technical Assistance Center" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.928.
- This funding opportunity was created on May 16, 2016 and posted on May 16, 2016.
- Applicants must submit their applications by Jul 14, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Jurisdictional Approach to Curing Hepatitis C Among HIV/HCV Coinfected People of Color - Evaluation and Technical Assistance Center (ETAC) opportunity (HRSA-16-188) is a fiscal year 2016 HRSA discretionary grant offered through a cooperative agreement. The award is intended to support one organization for up to three years to serve as a national-level hub that coordinates, supports, and evaluates the work of up to four Ryan White HIV/AIDS Program (RWHAP) Part A and Part B jurisdictions that are funded under a separate companion announcement (HRSA-16-189). In practical terms, the ETAC is not primarily a direct service grant for a single clinic or city; it is a backbone and support center designed to strengthen the ability of participating jurisdictions to build reliable, jurisdiction-wide systems for hepatitis C virus (HCV) screening, linkage to care, treatment, and cure for people living with HIV (PLWH), with a specific focus on HIV/HCV coinfected people of color.
The core purpose of the initiative is to expand jurisdiction-level capacity so that more HIV/HCV coinfected people of color are diagnosed, treated with curative HCV therapies, and ultimately cured. The opportunity explicitly highlights populations that experience disproportionate HCV coinfection and barriers to care, including Blacks/African Americans, Latinos/as, and American Indians/Alaska Natives. It also emphasizes groups with elevated HCV risk or ongoing transmission concerns, such as people who inject drugs (PWID). Men who have sex with men (MSM) are also noted as remaining at risk for incident HCV infection, reinforcing that the project is meant to address both long-standing disparities and emerging patterns of infection among PLWH.
The ETAC is expected to help the four funded RWHAP jurisdictions reach a goal of a centrally coordinated, comprehensive system for HCV screening, care, and treatment. The work is organized around three major responsibilities. First, the ETAC must deliver technical assistance and capacity-building assistance (TA/CBA) tailored to each jurisdiction so local programs can implement and sustain effective HCV care continuums within RWHAP-supported systems. Second, the ETAC must design and carry out a rigorous multisite evaluation across the jurisdictions to assess both how the systems are implemented and what outcomes they achieve, using a mixed-methods approach that includes quantitative and qualitative components. Third, the ETAC must lead the publication and dissemination of findings, including best practices and lessons learned, so that strategies proven effective in these four jurisdictions can be replicated more broadly. Because this is a cooperative agreement, the jurisdictions funded under HRSA-16-189 are expected to actively cooperate with the ETAC across planning, implementation, evaluation, and dissemination.
The timeline for deliverables is front-loaded in Year 1 to quickly identify gaps and shape support. By the second month of Year 1, the ETAC must develop two standardized assessments to be implemented by all four jurisdictions: a patient knowledge assessment focused on understanding of HCV treatment among coinfected consumers, and a provider knowledge assessment focused on clinician and healthcare staff knowledge about HCV screening and treatment in the context of HIV/HCV coinfection. The point of these early assessments is to surface concrete misunderstandings, informational barriers, training gaps, and practice-level needs that can be addressed through education, training, and on-the-ground systems improvements. Using results from these assessments, along with a separate needs assessment conducted by each jurisdiction, the ETAC must then produce a jurisdiction-specific TA/CBA plan by the ninth month of Year 1, ensuring that technical support is targeted rather than generic.
A central feature of the support model is a structured community of practice for the project directors from the four jurisdictions, facilitated by the ETAC. This community of practice is meant to function as a real-time learning network where sites compare approaches, troubleshoot implementation challenges, share workflows and tools, and accelerate improvement by learning from one another while the project is underway. In parallel, during the first half of Year 1, the ETAC is expected to develop the multisite evaluation plan, explicitly calling for mixed methods to capture both measurable outcomes (for example, screening rates, linkage to HCV care, treatment initiation and completion, and cure-related endpoints) and implementation processes (for example, barriers, facilitators, and how jurisdictional systems are built and coordinated).
Implementation activities intensify toward the end of Year 1. Beginning in the fourth quarter of Year 1, the ETAC is expected to roll out the TA/CBA plan, deliver individualized assistance to each jurisdiction, and formally launch the community of practice. The methods of technical assistance are designed to be continuous and multi-channel, including regular teleconferences, a web presence and webinars, annual site visits, and annual national working meetings coordinated by the ETAC and held in the Washington, DC area. Also beginning in the second half of Year 1, the ETAC starts implementing the multisite evaluation, with full cooperation from participating jurisdictions so data collection and learning can occur while systems are being built and refined.
In Year 2, the ETAC continues both the TA/CBA and the multisite evaluation, while also helping roll out National HCV Provider Competencies and a standardized curriculum. This curriculum component is implemented in partnership with the AIDS Education and Training Centers (AETCs), signaling that provider training is not meant to be ad hoc but aligned with broader national training infrastructure and standards. In Year 3, the ETAC transitions into more intensive analysis of process and outcome data and takes the lead on turning results into publications, products, and dissemination efforts. These dissemination activities are to be coordinated in collaboration with the HIV/AIDS Bureau (HAB) Special Projects of National Significance (SPNS) Program and the four jurisdictions, with an emphasis on producing actionable, transferable lessons for other RWHAP jurisdictions and stakeholders working to cure HCV among PLWH.
Administratively, the opportunity is issued by HHS HRSA, falls under CFDA 93.928, and anticipates one award. The application deadline listed is July 14, 2016, and the mechanism is a cooperative agreement, which typically means substantial federal involvement and close coordination with HRSA during the project period. While the award ceiling is listed as 0 in the provided source data (often a placeholder in some postings), the scope and specificity of required deliverables make clear that HRSA intended to fund a single capable organization to provide national coordination, structured technical assistance, robust evaluation, and broad dissemination for a focused, equity-centered effort to increase HCV cure among HIV/HCV coinfected people of color.
Frequently Asked Questions (FAQs)
What is the HRSA-16-188 ETAC grant opportunity?
HRSA-16-188 is a fiscal year 2016 HRSA discretionary grant offered through a cooperative agreement. It funds an Evaluation and Technical Assistance Center (ETAC) to serve as a national-level hub that coordinates, supports, and evaluates work happening in up to four Ryan White HIV/AIDS Program (RWHAP) Part A and Part B jurisdictions funded under a separate companion announcement (HRSA-16-189).
Is this funding meant to pay for direct patient services in one clinic, city, or state?
No. The ETAC is described as a backbone and support center rather than a direct service grant for a single clinic or city. Its role is to strengthen jurisdiction-wide systems for HCV screening, linkage to care, treatment, and cure among people living with HIV, with a focus on HIV/HCV coinfected people of color.
How many awards does HRSA expect to make under HRSA-16-188?
The opportunity anticipates one award to support one organization.
How long is the project period for the ETAC award?
The award is intended to support one organization for up to three years.
What is the main purpose of the ETAC initiative?
The core purpose is to expand jurisdiction-level capacity so that more HIV/HCV coinfected people of color are diagnosed, treated with curative HCV therapies, and ultimately cured. The ETAC supports jurisdictions in building reliable, centrally coordinated systems across the full HCV care continuum.
Which populations are specifically emphasized in this opportunity?
The opportunity explicitly highlights HIV/HCV coinfected people of color and notes disproportionate impact and barriers to care among Blacks/African Americans, Latinos/as, and American Indians/Alaska Natives. It also emphasizes groups with elevated HCV risk or transmission concerns such as people who inject drugs (PWID), and notes that men who have sex with men (MSM) remain at risk for incident HCV infection.
How does HRSA-16-188 relate to HRSA-16-189?
HRSA-16-188 funds the ETAC that coordinates, supports, and evaluates up to four RWHAP Part A and Part B jurisdictions. Those jurisdictions are funded through a separate companion announcement, HRSA-16-189. The ETAC and the HRSA-16-189 jurisdictions are expected to work together across planning, implementation, evaluation, and dissemination.
What does it mean that this award is a cooperative agreement?
The mechanism is a cooperative agreement, which is associated with substantial federal involvement and close coordination with HRSA during the project period. The opportunity also states that the funded jurisdictions are expected to actively cooperate with the ETAC throughout the work.
What are the three major responsibilities of the ETAC?
The work is organized around three major responsibilities: (1) deliver tailored technical assistance and capacity-building assistance (TA/CBA) to each jurisdiction; (2) design and carry out a rigorous multisite evaluation using a mixed-methods approach (quantitative and qualitative) to assess implementation and outcomes; and (3) lead publication and dissemination of findings, including best practices and lessons learned, so strategies can be replicated more broadly.
What is meant by a "jurisdiction-wide system" for HCV screening, care, and treatment?
In this opportunity, the ETAC is intended to help jurisdictions reach a goal of a centrally coordinated, comprehensive system that supports HCV screening, linkage to HCV care, treatment initiation and completion, and cure-related endpoints within RWHAP-supported systems.
What deliverables are required early in Year 1?
The timeline is front-loaded. By the second month of Year 1, the ETAC must develop two standardized assessments for use by all four jurisdictions: a patient knowledge assessment focused on understanding of HCV treatment among coinfected consumers, and a provider knowledge assessment focused on clinician and healthcare staff knowledge about HCV screening and treatment in the context of HIV/HCV coinfection.
What are the standardized assessments intended to accomplish?
They are intended to surface concrete misunderstandings, informational barriers, training gaps, and practice-level needs. The results are meant to inform education, training, and practical systems improvements in each participating jurisdiction.
When is the jurisdiction-specific TA/CBA plan due?
Using results from the standardized assessments and a separate needs assessment conducted by each jurisdiction, the ETAC must produce a jurisdiction-specific TA/CBA plan by the ninth month of Year 1.
What is the community of practice and who participates?
A central feature of the support model is a structured community of practice facilitated by the ETAC for the project directors from the four jurisdictions. It is designed as a real-time learning network where jurisdictions compare approaches, troubleshoot implementation challenges, and share workflows and tools while the project is underway.
When does the community of practice formally launch?
Beginning in the fourth quarter of Year 1, the ETAC is expected to roll out the TA/CBA plan, deliver individualized assistance to each jurisdiction, and formally launch the community of practice.
What does the multisite evaluation need to include?
The ETAC must develop an evaluation plan during the first half of Year 1 that explicitly uses mixed methods. The evaluation should capture measurable outcomes (such as screening rates, linkage to HCV care, treatment initiation and completion, and cure-related endpoints) and implementation processes (such as barriers, facilitators, and how jurisdictional systems are built and coordinated).
When does evaluation data collection begin?
In the second half of Year 1, the ETAC starts implementing the multisite evaluation, with full cooperation from participating jurisdictions, so that data collection and learning occur while systems are being built and refined.
What technical assistance methods are expected?
Technical assistance is intended to be continuous and multi-channel. The opportunity lists regular teleconferences, a web presence and webinars, annual site visits, and annual national working meetings coordinated by the ETAC and held in the Washington, DC area.
What happens in Year 2 of the ETAC project?
In Year 2, the ETAC continues TA/CBA and the multisite evaluation, and also helps roll out National HCV Provider Competencies and a standardized curriculum. The curriculum is implemented in partnership with the AIDS Education and Training Centers (AETCs), aligning provider training with broader national training infrastructure and standards.
What happens in Year 3 of the ETAC project?
In Year 3, the ETAC shifts toward more intensive analysis of process and outcome data and takes the lead on turning results into publications, products, and dissemination efforts.
Who is involved in dissemination and publication of findings?
Dissemination activities are to be coordinated in collaboration with the HIV/AIDS Bureau (HAB) Special Projects of National Significance (SPNS) Program and the four jurisdictions, with an emphasis on producing actionable and transferable lessons for other RWHAP jurisdictions and stakeholders.
Where are the national working meetings held?
The opportunity specifies that annual national working meetings coordinated by the ETAC are held in the Washington, DC area.
What is the CFDA number and which agency issues this opportunity?
The opportunity is issued by HHS HRSA and falls under CFDA 93.928.
What was the application deadline listed for HRSA-16-188?
The application deadline listed is July 14, 2016.
How many jurisdictions does the ETAC support and evaluate?
The ETAC is intended to coordinate, support, and evaluate the work of up to four RWHAP Part A and Part B jurisdictions funded under the companion announcement.
What kinds of outcomes are explicitly mentioned for the evaluation?
The opportunity provides examples including screening rates, linkage to HCV care, treatment initiation and completion, and cure-related endpoints, alongside process measures about barriers, facilitators, and system-building.
Is the award amount clearly stated?
The award ceiling is listed as 0 in the provided source data, which is noted as often being a placeholder in some postings. The narrative description indicates HRSA intended to fund a single capable organization to provide national coordination, structured technical assistance, robust evaluation, and broad dissemination.
Browse more opportunities from the same agency: HHS-HRSA
Browse more opportunities from the same category: Health
Next opportunity: Cooperative Ecosystem Studies Unit, Gulf Coast CESU
Previous opportunity: NOTICE OF INTENT TO AWARD - Collaborate on the Execution of the Annual Work Plan of John H. Chafee Blackstone River Valley National Heritage Corridor, Inc.
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for HRSA 16 188
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (HRSA 16 188) also looked into and applied for these:
| Funding Opportunity |
|---|
| Inclusion of Mobile/e-Consents for Alzheimer's Disease Research (Admin Supp) Apply for PA 16 259 Funding Number: PA 16 259 Agency: HHS-NIH11 Category: Health Funding Amount: $100,000 |
| Jurisdictional Approach to Curing Hepatitis C among HIV/HCV Coinfected People of Color – Jurisdictional Sites Apply for HRSA 16 189 Funding Number: HRSA 16 189 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R01) Apply for PAR 16 265 Funding Number: PAR 16 265 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Reducing the Duration of Untreated Psychosis in the United States (R34) Apply for PAR 16 264 Funding Number: PAR 16 264 Agency: HHS-NIH11 Category: Health Funding Amount: $225,000 |
| Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01) Apply for PAR 16 262 Funding Number: PAR 16 262 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities Outside the United States Apply for CDC RFA IP16 1603 Funding Number: CDC RFA IP16 1603 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $400,000 |
| NHLBI Career Transition Award for Intramural Fellows (K22) Apply for PAR 16 267 Funding Number: PAR 16 267 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Surveillance and Response to Seasonal and Pandemic Influenza by Regional Offices of the World Health Organization Apply for CDC RFA IP16 1606 Funding Number: CDC RFA IP16 1606 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $2,000,000 |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP16 1604 Funding Number: CDC RFA IP16 1604 Agency: HHS-CDC-NCIRD Category: Health Funding Amount: $250,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 16 269 Funding Number: PAR 16 269 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Partnerships for Structure-Based Design of Novel Immunogens for Vaccine Development (R01) Apply for RFA AI 16 047 Funding Number: RFA AI 16 047 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Limited Competition: Small Grant Program for NIAMS K08 and K23 Recipients (R03) Apply for PAR 16 268 Funding Number: PAR 16 268 Agency: HHS-NIH11 Category: Health Funding Amount: $50,000 |
| NIAID Clinical Trial Implementation Cooperative Agreement (U01) Apply for PAR 16 270 Funding Number: PAR 16 270 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 16 272 Funding Number: PAR 16 272 Agency: HHS-NIH11 Category: Health Funding Amount: $150,000 |
| NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44) Apply for PAR 16 271 Funding Number: PAR 16 271 Agency: HHS-NIH11 Category: Health Funding Amount: Case Dependent |
| Healthy Tomorrows Partnership for Children Program (HTPCP) Apply for HRSA 17 008 Funding Number: HRSA 17 008 Agency: HHS-HRSA Category: Health Funding Amount: Case Dependent |
| Improving Sexually Transmitted Disease Programs through Assessment, Assurance, Policy Development, and Prevention Strategies (STD AAPPS) Apply for CDC RFA PS14 140204CONT17 Funding Number: CDC RFA PS14 140204CONT17 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| CDC’s National Undergraduate Student Program: A Public Health Workplace Experience to Increase Student Interest in Public Health Apply for CDC RFA MN11 110106CONT16 Funding Number: CDC RFA MN11 110106CONT16 Agency: HHS-CDC Category: Health Funding Amount: Case Dependent |
| Fogarty Global Health Training Program (D43) Apply for RFA TW 16 002 Funding Number: RFA TW 16 002 Agency: HHS-NIH11 Category: Health Funding Amount: $1,100,000 |
| Surveillance, intervention, and referral to services activities for infants with microcephaly or other adverse outcomes linked with the Zika virus Apply for CDC RFA DD16 1605 Funding Number: CDC RFA DD16 1605 Agency: HHS-CDC-NCBDDD Category: Health Funding Amount: $360,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "HRSA 16 188", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.